The study is double-blind and randomized, which means the treatment is assigned by chance and neither the participants nor the study team knows who receives which treatment during the study. The study has two parts. In the first part, the focus is on safety and how well the treatment is tolerated. In the second part, the focus is on whether the treatment helps improve symptoms over time. During the study, blood samples may be taken to look at levels of certain immune proteins, called IgG, IgM, and IgA, and to check for antibodies against the study drug.

Aritinercept is described as a dual BAFF/APRIL inhibitor, meaning it blocks two signals in the immune system that can help immune cells survive and stay active. This may reduce the immune attack that contributes to symptoms in generalized myasthenia gravis.

The purpose of the study is to assess whether povetacicept is safe and well‑tolerated in adults with this disease. Participants are randomly assigned to receive either the study drug or the placebo and attend regular clinic visits over several weeks, during which they receive the assigned treatment and undergo routine health checks.

Key assessments include measuring the level of immunoglobulin G, a type of antibody that helps the immune system, to see how it changes during treatment, and monitoring for any side effects or serious health problems. All observations are recorded to determine the overall safety profile of the medication.

The purpose of the study is to understand how the body of children and teenagers processes inebilizumab, how the medication affects certain immune cells in the blood, and whether it is safe and well-tolerated in this age group. The study will measure how much of the medication is present in the blood over time, how it affects the number of specific immune cells known as CD20-positive B-cells, and whether any side effects occur during treatment. Participants may continue taking their current medications for myasthenia gravis, which could include steroids, other immune-suppressing medicines such as azathioprine, mycophenolate mofetil, or mycophenolic acid, and medications that help with muscle strength like pyridostigmine.

During the study, doctors will regularly check participants through blood tests and measurements of muscle strength and daily activities to see how the disease is responding to treatment. The study will also look at whether the body develops any immune response against the medication itself. All participants will receive the active treatment as this is an open-label study, meaning everyone will know they are receiving inebilizumab rather than a placebo.

The purpose of the study is to evaluate the long-term safety of KYV-101. Participants will be monitored over an extended period to observe how the body reacts to the medication over time. This involves checking for the development of new health issues, such as malignancy, which refers to cancerous growths, or any changes in existing neurologic conditions, which are related to the brain and nervous system. The study also tracks changes in rheumatologic issues, which involve the joints and connective tissues, or hematologic disorders, which are conditions affecting the blood.

The research involves the use of two medications: efgartigimod alfa and empasiprubart. Both of these are administered through an IV infusion, which is a method of delivering medication directly into a vein. Some participants will receive efgartigimod alfa alone, while others will receive empasiprubart as an additional treatment added to their current efgartigimod alfa therapy. This approach is intended for individuals who have experienced only a partial improvement in their symptoms while using the first medication.

During the study, participants will follow a specific treatment schedule to observe how the medications affect their condition and overall health. Monitoring will include checking vital signs and conducting an ECG, which is a test that records the electrical activity of the heart, to ensure the treatments are tolerated well. The study aims to observe changes in how much the disease impacts daily activities and the severity of muscle weakness over time.

Participants in the study will receive either IM-101 or a placebo, which is a substance that does not contain active medication, through an intravenous injection, a method where medicine is delivered directly into a vein. The research will involve different groups of people receiving various amounts of the medication to see how the body processes it and how it affects the disease. The study aims to determine if the treatment is safe, how well it is tolerated, and if it helps improve muscle strength and daily activities over a set period of time.

The purpose of this study is to find out if cladribine capsules can improve symptoms of Generalized Myasthenia Gravis compared to placebo. The study will measure how well participants can perform daily activities and how strong their muscles are. It will also look at how cladribine affects quality of life for people living with this condition. The researchers want to understand if this treatment is safe and whether it causes any unwanted effects.

The study is divided into three periods and participants will be randomly assigned to receive either a high dose of cladribine, a low dose of cladribine, or placebo. During the study, participants will continue taking any other medications they were already using for their condition, such as steroids or medicines that help with muscle function. The researchers will regularly check muscle strength and the ability to do everyday tasks like talking, chewing, swallowing, and using arms and legs. Blood tests and other safety checks will be done throughout the study to monitor participants’ health. If needed, some participants may receive additional treatment during the study.

The study will include different groups of people. Some will receive nipocalimab, some will receive efgartigimod, and another group will include people who are already taking efgartigimod and will switch to nipocalimab during the study. People in the study must be adults between 18 and 74 years old and must have specific antibodies called AChR antibodies in their blood. They should also have symptoms that affect more than just their eye muscles and should not be responding well enough to their current treatment.

During the study, the main measurement will look at changes in the levels of a substance called total IgG in the blood between weeks 8 and 12 in those receiving nipocalimab compared to those receiving efgartigimod. The treatment period will last up to several months depending on which group a person is in. The study will help doctors understand whether one medication might work better than the other for treating generalized myasthenia gravis.

The study aims to determine how well IMVT-1402 works and how safe it is for patients with mild to severe forms of the disease. The medication is given as a subcutaneous injection, which means it is injected under the skin. Some participants will receive IMVT-1402, while others will receive a placebo during the study.

The treatment period lasts 26 weeks, during which participants will receive regular doses of either IMVT-1402 or placebo. The study will measure how the treatment affects participants’ ability to perform daily activities and their overall muscle strength. Throughout the study, participants will be monitored for any changes in their condition and any potential side effects of the treatment.

The purpose of this research is to evaluate if TOL2 is safe and well-tolerated by patients who have myasthenia gravis with positive acetylcholine receptor antibodies. This is the first time this medication is being tested in humans. The study will test both single doses and multiple doses of the medication, comparing it to placebo.

During the study, participants will receive either TOL2 or placebo through intravenous infusions. The study will monitor various aspects of patients’ health, including their daily activities, quality of life, and any changes in their condition. Doctors will regularly check blood tests, vital signs, and perform physical examinations to ensure patient safety throughout the treatment period.

The research aims to determine if Descartes-08 can improve the ability to perform daily activities in people with Generalized Myasthenia Gravis. The treatment is administered through intravenous infusion, and participants will receive either Descartes-08 or placebo. The study will monitor patients for 4 months to assess changes in their symptoms and ability to perform everyday tasks.

The medication being tested is a type of cell therapy that uses the patient’s own immune cells that have been modified in a laboratory. These cells are specifically designed to target and fight the mechanisms causing muscle weakness in Generalized Myasthenia Gravis. Throughout the study, participants will undergo regular evaluations to measure their muscle strength and daily functioning abilities.

The purpose of the study is to assess how effective, safe, and tolerable remibrutinib is for patients with generalized myasthenia gravis. Participants in the study will be randomly assigned to receive either remibrutinib or a placebo, which looks like the medication but does not contain the active ingredient. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This phase of the study will last for six months, after which there will be an open-label extension phase where all participants may receive remibrutinib.

Throughout the study, the main focus will be on changes in the participants’ ability to perform daily activities, as measured by a specific scale called the Myasthenia Gravis Activity of Daily Living (MG-ADL) scale. The study will also monitor other health indicators and any side effects that may occur. The goal is to determine if remibrutinib can help reduce the symptoms of generalized myasthenia gravis and improve the quality of life for those affected by this condition.

The purpose of the study is to understand how Gefurulimab works in the body, how safe it is, and how effective it is in treating children with this specific type of gMG. Participants in the study will receive the medication and be monitored over a period of time to see how their bodies respond to the treatment. The study will also look at how the medication affects the symptoms of gMG and whether it helps improve muscle strength and daily activities.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. These check-ups will include assessments of vital signs, physical examinations, and laboratory tests. The study aims to gather important information that could help improve treatment options for children with Generalized Myasthenia Gravis in the future.

The purpose of the study is to assess the safety of YTB323 in patients with gMG who have antibodies against specific proteins called AChR or MuSK. The study will also look at how the treatment affects the body over time. Participants will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. The study will monitor participants for any side effects and changes in their health, including vital signs and laboratory tests.

In addition to YTB323, the study involves other medications such as Fludarabine Phosphate, Tocilizumab, Cyclophosphamide, and Flebogamma DIF, which are used to prepare the body for the main treatment or manage symptoms. The study will take place over several years, with regular check-ups to track the progress and effects of the treatment. Participants will be closely monitored to ensure their safety and to gather information on how well the treatment works in managing the symptoms of gMG.

Participants in the study will receive Rituximab through an intravenous injection, which means it will be administered directly into a vein. The study will also involve the use of other medications, such as Prednisone, a corticosteroid taken orally in tablet form, and Sodium Chloride, which is a solution used for infusion. Some participants may receive a placebo instead of the active medication. The study will last for a period of up to 12 months, during which participants will have regular check-ups to monitor their health and the effects of the treatment.

The purpose of the study is to determine if Rituximab can help reduce the symptoms and improve the quality of life for people with Myasthenia Gravis. Participants will be closely monitored for any changes in their condition and any side effects they may experience. The study will also assess whether the use of Rituximab can lead to a reduction in the need for other medications, such as corticosteroids, which are commonly used to manage the symptoms of Myasthenia Gravis.

The purpose of the study is to evaluate how effective and tolerable efgartigimod is when used early in the treatment of patients with generalized myasthenia gravis. Participants in the study will receive efgartigimod along with their usual treatment regimen, which may include a medication called prednisone. The study will monitor changes in the participants’ ability to perform daily activities and other health indicators over several weeks.

Throughout the study, participants will have regular assessments to track their progress. These assessments will occur at various intervals, such as weeks 4, 6, 8, 16, and 28, to see how the treatment affects their condition over time. The study aims to understand how quickly efgartigimod can improve symptoms and how it impacts the overall quality of life for those with generalized myasthenia gravis. Additionally, the study will observe any side effects or adverse events that may occur during the treatment period.

The purpose of the study is to assess the safety and tolerability of DNTH103 in adults with gMG over a period of 13 weeks. Participants will receive either DNTH103 or a placebo through intravenous (IV) or subcutaneous (SC) injections. The study will monitor the participants for any side effects and measure the levels of DNTH103 in their blood. Additionally, the study will evaluate the effectiveness of DNTH103 in improving symptoms of gMG by using various scales that measure muscle strength and daily living activities.

Participants in the study will be adults aged 18 to 75 who have been diagnosed with gMG for at least three months. They will need to have received certain vaccinations against bacterial infections before joining the study. The trial will last up to 52 weeks, with the main focus on the first 13 weeks. During this time, the safety and any potential side effects of DNTH103 will be closely monitored. The study aims to provide valuable information on the potential benefits and risks of using DNTH103 for treating gMG.

The purpose of this study is to evaluate how safe and tolerable zilucoplan sodium is for patients who have already participated in a previous study involving this medication. Participants will receive the treatment over an extended period to monitor its effects and any potential side effects. The study will not involve any new medications or diseases, focusing solely on zilucoplan sodium and generalized myasthenia gravis.

Throughout the study, participants will be regularly assessed to ensure their well-being and to gather information on how the treatment impacts their daily activities and quality of life. The study aims to provide valuable insights into the long-term use of zilucoplan sodium for managing symptoms of generalized myasthenia gravis.

Participants in the study will receive the treatment through a subcutaneous injection, which means it is injected under the skin. The study will monitor how the body processes the treatment and its effects on the disease. This includes checking the levels of certain proteins in the blood and observing any changes in the symptoms of Generalized Myasthenia Gravis. The study will also look at the safety of the treatment by recording any side effects and changes in health indicators like heart rate and blood tests.

The study will take place over a period of time, during which participants will have regular check-ups to assess their response to the treatment. The goal is to gather information that will help determine the best way to use efgartigimod PH20 SC in treating children with Generalized Myasthenia Gravis. This research is important for understanding how to manage this condition in younger patients and improve their quality of life.

Participants in the study will receive efgartigimod alfa in one of two dosing regimens. The study will compare a continuous regimen, where the medication is given every two weeks, to a cyclic regimen, where the medication is given in cycles. The study will monitor changes in the participants’ symptoms over time to determine which dosing schedule is more effective. The study will also track any side effects or adverse events that participants may experience during the trial.

The trial aims to provide valuable information on how to best use efgartigimod alfa to help manage symptoms of Generalized Myasthenia Gravis. By comparing different dosing regimens, researchers hope to find the most effective way to use this treatment to improve the quality of life for individuals living with this condition.

Participants in the study will receive either the Efgartigimod IV treatment or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will follow a structured plan over a period of time, during which participants will be monitored for changes in their symptoms and any side effects they may experience.

The trial aims to provide valuable information about the potential benefits of Efgartigimod IV for people with Generalized Myasthenia Gravis who are seronegative for acetylcholine receptor binding antibodies. By comparing the effects of the treatment to those of a placebo, researchers hope to better understand how this medication can help manage the condition and improve the quality of life for those affected. Participants will be closely observed throughout the study to ensure their safety and to gather comprehensive data on the treatment’s impact.

Participants in the study will receive either the intravenous or subcutaneous form of efgartigimod over a period of time. The study will monitor the occurrence and severity of any side effects, as well as changes in laboratory test results, vital signs, and other health indicators. The study will also look at the presence of any antibodies that might develop against efgartigimod or the enzyme used in the subcutaneous form, known as recombinant human hyaluronidase PH20.

The purpose of this study is to ensure that the treatment is safe for long-term use in children with Generalized Myasthenia Gravis. By carefully observing the effects of the treatment, researchers hope to gather important information that could lead to better management of this condition in the future.

Participants in the study will receive Rozanolixizumab over a period of six weeks. During this time, researchers will monitor how the drug moves through the body and its effects on the disease. The study will also look at any side effects that may occur, including serious ones that might lead to stopping the treatment. Additionally, the study will measure changes in certain proteins in the blood, known as immunoglobulins, and specific antibodies related to myasthenia gravis. These measurements will help determine if the treatment is working and how it affects the participants’ daily activities and overall condition.

The study is designed to last up to 18 weeks, including the treatment and observation periods. Throughout the study, researchers will evaluate the local tolerability of the treatment, which means they will check how the skin and body react to the injections. The study aims to provide valuable information on the potential benefits and risks of using Rozanolixizumab in young patients with generalized myasthenia gravis, contributing to better understanding and management of this condition.

Participants in the study will receive treatment cycles with rozanolixizumab over a period of time. The study will monitor for any serious side effects or adverse events that may occur during the treatment. Additionally, the study will look at changes in the levels of a protein in the blood called Immunoglobulin G (IgG), which plays a role in the immune system, as well as changes in the symptoms of myasthenia gravis. The study aims to provide valuable information on how well the treatment works and how safe it is for children with generalized myasthenia gravis.

Throughout the study, participants will be closely observed to ensure their safety and to gather data on the effectiveness of rozanolixizumab. The study is designed to help understand if this treatment can be a viable option for managing symptoms in children with generalized myasthenia gravis, potentially improving their quality of life. The study is expected to continue until 2027, providing a comprehensive evaluation of the treatment’s impact over time.

Participants in the study will receive either the treatment plan involving corticosteroids and rituximab or a different approach, which may include a placebo. The study will monitor the participants over time to see how many develop generalized myasthenia gravis, where symptoms affect more than just the eye muscles. The study will also compare the severity of symptoms, the number of hospital visits, and the quality of life between the two groups.

The medications used in this study include POLARAMINE (dexchlorpheniramine maleate), IMUREL (azathioprine), Rixathon (rituximab), PARACETAMOL PANPHARMA (paracetamol), CORTANCYL (prednisone), and SOLUMEDROL (methylprednisolone hemisuccinate). These medications are administered in various forms, such as injections or tablets, depending on the specific treatment plan. The study will last for several years, with regular check-ups to assess the effectiveness and safety of the treatments.

During the study, participants will receive ublituximab and may also receive other medications such as methylprednisolone, cetirizine, paracetamol, diphenhydramine, dexamethasone, and sodium chloride. These medications are commonly used to manage symptoms or support the treatment process. The study will monitor how ublituximab is absorbed, distributed, and eliminated by the body, as well as its effects on certain immune cells called B-cells.

The trial will take place over several years, with participants attending regular visits to receive the medication and undergo assessments. These assessments will help researchers gather important information about the safety and effectiveness of ublituximab in treating these autoimmune conditions. The study aims to provide valuable insights that could improve treatment options for patients with Myasthenia Gravis and Relapsing Multiple Sclerosis.

The study is designed to compare the effects of inebilizumab with a placebo, which is a substance with no active medication. Participants in the study will receive either inebilizumab or the placebo. The study will last for a period of time, during which participants will receive regular doses of the treatment. The goal is to observe any changes in the participants’ ability to perform daily activities and to assess the overall safety and effectiveness of inebilizumab.

Throughout the study, participants will be monitored for any side effects or changes in their condition. The study will also look at how inebilizumab affects the use of other medications, such as corticosteroids, which are often used to manage myasthenia gravis. By the end of the study, researchers hope to determine if inebilizumab can provide a meaningful improvement in the lives of those living with myasthenia gravis.

The purpose of the study is to determine how well Gefurulimab works in improving the daily living activities of adults with Generalized Myasthenia Gravis. Participants in the study will receive either the treatment or a placebo and will be monitored over a period of time to observe any changes in their condition. The study aims to see if there is a significant improvement in the ability to perform daily activities and a reduction in muscle weakness.

Throughout the study, participants will undergo regular assessments to track their progress and any changes in their symptoms. The study is designed to provide valuable information on the potential benefits of Gefurulimab for individuals living with Generalized Myasthenia Gravis, contributing to the understanding of how this treatment can help manage the disease.

The purpose of the study is to understand how safe and tolerable KYV-101 is for patients, as well as how effective it might be in treating the disease. Participants in the study will receive the treatment through an intravenous infusion, which means the medicine is given directly into a vein. The study will follow participants over a period of time to monitor their health and any changes in their condition. This includes checking for any side effects and measuring the strength and function of their muscles.

Throughout the study, researchers will collect information on various health markers, such as the presence of specific antibodies and the levels of certain cells in the blood. This will help them understand how the treatment is working and its impact on the disease. The study aims to provide valuable insights into the potential benefits of KYV-101 for people living with refractory generalized myasthenia gravis.

The purpose of the study is to evaluate the effectiveness and safety of NMD670 over a period of 21 days. Participants will be randomly assigned to receive either NMD670 or a placebo, which looks like the real medication but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, participants will take the medication orally and will be monitored by healthcare professionals to assess any changes in their condition. The main goal is to observe any improvements in muscle strength and overall symptoms of Myasthenia Gravis. The study aims to provide valuable information on the potential benefits of NMD670 for managing this condition.

Participants in the study will receive efgartigimod alfa through a vein, and the study will monitor how the body processes the medication and how it affects the disease. The study will also look at the safety of the treatment and any side effects that may occur. The trial aims to provide evidence of how well the treatment works in children with Generalized Myasthenia Gravis.

Throughout the study, researchers will collect information on the levels of certain proteins in the blood, such as total IgG and anti-acetylcholine receptor antibodies, which are important in understanding the disease and the treatment’s effects. The study will also assess changes in the participants’ quality of life and any improvements in their symptoms. The trial is expected to continue until March 2025.

The study will begin with a phase where neither the participants nor the researchers know who is receiving iptacopan and who is receiving the placebo. This is known as a “double-blind” study. After this phase, there will be an “open label” phase where all participants will receive iptacopan. The study will last for several months, and participants will be monitored to see how their symptoms change over time. The main goal is to see if iptacopan can help reduce the symptoms of gMG, as measured by a specific scale that assesses daily living activities affected by the disease.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their condition. The study will also look at any side effects that might occur with the use of iptacopan. This research aims to provide more information about the potential benefits and risks of using iptacopan for treating generalized Myasthenia Gravis.

The study is divided into two parts. In the first part, participants will be randomly assigned to receive either Vimseltinib or a placebo, which looks like the medication but does not contain the active ingredient. This part of the study is double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication. In the second part, all participants will receive Vimseltinib, and this phase is open-label, meaning everyone will know they are receiving the medication.

Participants will take the medication orally and will be monitored over a period of time to assess the response of their tumor to the treatment. The study will also look at changes in joint movement, pain levels, and overall physical function. The goal is to see if Vimseltinib can reduce the size of the tumor and improve symptoms without causing significant side effects. The study will help determine if Vimseltinib is a viable treatment option for people with Tenosynovial Giant Cell Tumor.

The purpose of the study is to evaluate how effective and safe Batoclimab is as a treatment for adults with Generalized Myasthenia Gravis. Participants in the study will receive either Batoclimab or a placebo. The study will monitor changes in the participants’ ability to perform daily activities, which is an important measure of how the disease affects their lives. The trial will last for several weeks, during which participants will receive regular injections and attend follow-up visits to assess their progress.

Throughout the study, researchers will carefully observe the participants to see how their symptoms change and to ensure their safety. The goal is to determine if Batoclimab can help improve the quality of life for people living with Generalized Myasthenia Gravis by reducing muscle weakness and improving their ability to carry out daily tasks. This study is an important step in finding new and effective treatments for this challenging condition.

The purpose of the study is to evaluate the safety and effectiveness of using the Zilucoplan auto-injector for self-administration by participants with Generalized Myasthenia Gravis. Participants will be asked to use the auto-injector to administer the medication themselves. The study will monitor how well participants can manage the self-injection process and will also keep track of any side effects or adverse reactions that may occur during the study period.

The study will take place over several visits, where participants will be observed and supported in using the auto-injector. The goal is to ensure that the auto-injector is a safe and effective way for people with Generalized Myasthenia Gravis to manage their treatment independently. Participants will be closely monitored for any serious or non-serious side effects related to the medication or the device used for administration.

The main goal of the study is to evaluate how effective nipocalimab is in improving the daily living activities of people with Generalized Myasthenia Gravis. Participants in the study will receive either nipocalimab or a placebo, and their progress will be monitored over a period of time. The study will look at changes in their ability to perform daily activities and any side effects they might experience.

Participants will be randomly assigned to receive either the treatment or the placebo, and neither the participants nor the researchers will know who is receiving which, to ensure unbiased results. The study will take place over several weeks, and participants will have regular check-ups to assess their health and the effects of the treatment. The information gathered from this study will help determine if nipocalimab is a safe and effective treatment option for people with Generalized Myasthenia Gravis.

Participants in the study will receive zilucoplan sodium once a day for a period of time. The study will monitor how the medication affects the body and any side effects that may occur. The study will also look at changes in the participants’ ability to perform daily activities and their overall quality of life. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of zilucoplan sodium.

The study aims to gather information on how zilucoplan sodium can help manage symptoms of generalized myasthenia gravis in children and to ensure it is safe for use in this age group. The results will help determine if this treatment can be a beneficial option for managing this condition in young patients.

Participants in this study will receive zilucoplan sodium through daily injections for up to 52 weeks. The study will monitor the occurrence of any side effects or adverse events that may arise during this period. Additionally, the study will assess the levels of zilucoplan sodium in the blood and its impact on certain biological markers related to the disease. The study will also evaluate how the medication affects the participants’ ability to perform daily activities and their overall muscle strength.

This study is an extension of a previous research project involving zilucoplan sodium, and it is designed to provide further insights into the medication’s long-term use in treating generalized myasthenia gravis in children. Participants who have completed the earlier study and for whom continued treatment is deemed beneficial by their healthcare provider may be eligible to participate in this extension study.

Participants in the study will receive nipocalimab and will be monitored over a period of time to see how their bodies respond to the treatment. The study will look at various aspects, such as the effect of nipocalimab on certain proteins in the blood and any side effects that may occur. The study aims to gather information on how the medication is processed in the body and its overall impact on the disease.

This trial is open-label, meaning that both the participants and the researchers know what treatment is being given. The study does not involve a placebo, and all participants will receive the active medication. The information collected from this study will help in understanding the potential benefits and risks of using nipocalimab in treating generalized myasthenia gravis in children and teenagers.

Participants in the study will receive either Cladribine or a placebo, in addition to their regular treatment. The study will take place over several weeks, during which participants will have regular visits to monitor their health and the effects of the treatment. These visits will include assessments of how the disease affects daily activities and whether there is a need for additional treatments. The study will also look at changes in certain blood markers related to the disease.

Throughout the trial, the safety of the participants will be closely monitored, with regular checks on various health parameters such as blood counts and liver function. The study aims to provide valuable information on whether adding Cladribine to the treatment plan can help improve the management of Myasthenia Gravis and reduce the need for other medications like steroids. The trial is expected to continue until 2026, with the goal of improving treatment options for those affected by this condition.